文献速递浆细胞疾病造血干细胞移植与细胞治疗

全球新诊断多发性骨髓瘤自体造血干细胞移植的特征与结局:世界血液与骨髓移植网络(WBMT)研究

Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).
PubMed 文献 · Am J Hematol · 2024-08-19

该研究收集9个国家/国际注册中心2013至2017年间61725例新诊断多发性骨髓瘤患者首次自体造血细胞移植的基线特征与结局。中位总生存90.2个月(95%CI 88.2-93.6),中位无进展生存36.5个月(95%CI 36.1-37.0);24个月累积复发率33%(95%CI 32.5%-33.4%),非复发死亡率2.5%(95%CI 2.3%-2.6%)。结论认为自体造血细胞移植安全有效,各注册中心间结局存在差异。

要点

  • 中位总生存90.2个月(95%CI 88.2-93.6),中位无进展生存36.5个月(95%CI 36.1-37.0)。
  • 24个月累积复发率33%(95%CI 32.5%-33.4%),非复发死亡率2.5%(95%CI 2.3%-2.6%)。
  • 多因素分析中年轻年龄、IgG型、移植时完全血液学缓解、KPS 100%、ISS I期、HCT-CI 0、标准细胞遗传学风险、近年移植及来那度胺维持与更优结局相关。

核心结论

  • 全球数据表明多发性骨髓瘤自体造血细胞移植是安全有效的治疗,非复发死亡率为1%-3%,总生存、无进展生存、复发率及患者特征存在明显地区差异。
  • 移植后维持治疗对总生存有有利影响。

研究设计与样本

  • 研究收集来自9个国家/国际注册中心的61725例2013至2017年间接受首次自体造血细胞移植的新诊断多发性骨髓瘤患者的基线特征与结局数据。
  • 主要终点为总生存,次要终点为无进展生存、复发率和非复发死亡率。

主要发现

  • 中位总生存90.2个月(95%CI 88.2-93.6),中位无进展生存36.5个月(95%CI 36.1-37.0)。
  • 24个月累积复发率33%(95%CI 32.5%-33.4%),非复发死亡率2.5%(95%CI 2.3%-2.6%)。
  • 多因素分析中更优结局与以下因素相关:较年轻年龄、IgG亚型、自体移植时完全血液学缓解、Karnofsky评分100%、国际分期系统(ISS)I期、HCT合并症指数(CI)0、标准细胞遗传学风险、近年接受自体移植以及使用来那度胺维持治疗。
  • 各注册中心间基线特征和结局存在差异;全球12个月非复发死亡率为1%-3%,36个月总生存为69%-84%,12个月复发率为12%-24%,36个月无进展生存为43%-63%。
  • 这些结局的差异可归因于患者和疾病特征差异以及维持治疗的使用和宏观经济因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected data on baseline characteristics and outcomes from 61 725 patients with newly diagnosed MM who underwent upfront AHCT between 2013 and 2017 from nine national/international registries. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), relapse incidence (RI) and non-relapse mortality (NRM). Median OS amounted to 90.2 months (95% CI 88.2-93.6) and median PFS 36.5 months (95% CI 36.1-37.0). At 24 months, cumulative RI was 33% (95% CI 32.5%-33.4%) and NRM was 2.5% (95% CI 2.3%-2.6%). In the multivariate analysis, superior outcomes were associated with younger age, IgG subtype, complete hematological response at auto-HCT, Karnofsky score of 100%, international staging scoring (ISS) stage 1, HCT-comorbidity index (CI) 0, standard cytogenetic risk, auto-HCT in recent years, and use of lenalidomide maintenance. There were differences in the baseline characteristics and outcomes between registries. While the NRM was 1%-3% at 12 months worldwide, the OS at 36 months was 69%-84%, RI at 12 months was 12%-24% and PFS at 36 months was 43%-63%. The variability in these outcomes is attributable to differences in patient and disease characteristics as well as the use of maintenance and macroeconomic factors. In conclusion, worldwide data indicate that AHCT in MM is a safe and effective therapy with an NRM of 1%-3% with considerable regional differences in OS, PFS, RI, and patient characteristics. Maintenance treatment post-AHCT had a beneficial effect on OS.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Garderet L, Gras L, Koster L, et al. Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT). Am J Hematol. 2024. PMID: 39158218. doi:10.1002/ajh.27451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。